NSABP B-31

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是：1）在可手术的、组织学淋巴结阳性的、HER 2蛋白过表达的乳腺癌患者中，比较4个周期的阿霉素和环磷酰胺（AC）随后4个周期的泰素与相同化疗方案加赫赛汀的心脏毒性;以及2）确定在该患者群体中，4个周期AC后4个周期紫杉醇和每周赫赛汀治疗1年在延长生存期方面比4个周期AC后4个周期更有效紫杉醇。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of the study are 1) to compare the cardiotoxicity of four cycles of Adriamycin and Cyclophosphamide (AC) followed by four cycles of Taxol, with that of the same chemotherapy regimen plus Herceptin, in patients with operable, histologically node-positive breast cancer which overexpresses the HER2 protein; and 2)to determine whether, in this patient population, four cycles of AC followed by four cycles of Taxol and weekly Herceptin for one year is more effective in prolonging survival than four cycles of AC followed by four cycles of Taxol.